This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

St. Jude Medical Reports First Quarter 2014 Results

St. Jude Medical, Inc. (NYSE:STJ) today reported sales and net earnings for the first quarter ended March 29, 2014.

First quarter highlights:

  • Constant currency sales increased 4 percent and adjusted net earnings per share increased 9 percent on a constant currency basis, demonstrating our continued ability to deliver EPS leverage
  • U.S. ICD sales increased 5 percent driven by our leadership position in quadripolar CRT therapy
  • The company announced four new CRM product approvals in the U.S., which are expected to accelerate sales in the second half of 2014
  • The company announced CE Marking and European launch of its Prodigy™ Chronic Pain System, the first and only implantable neuromodulation system that delivers Burst Technology

First Quarter 2014 Sales

The company reported net sales of $1.363 billion in the first quarter of 2014, a 2 percent increase over net sales of $1.338 billion in the first quarter of 2013. Unfavorable foreign currency translation comparisons decreased first quarter sales by approximately $25 million. On a constant-currency basis, net sales increased by 4 percent over the first quarter of 2013.

Commenting on the company’s financial results, St. Jude Medical Chairman, President and Chief Executive Officer Daniel J. Starks said, “St. Jude Medical delivered a solid first quarter by meeting or exceeding our expectations in each of our technology platforms. These results reinforce our confidence that we are on track to accelerate sales growth as our product mix shifts to faster growing markets and as we continue to launch new products that improve patient outcomes, ensure the highest quality and lower the costs of treating expensive epidemic diseases.”

Cardiac Rhythm Management (CRM)

Total CRM sales, which include implantable cardioverter defibrillator (ICD) and pacemaker products, were $687 million for the first quarter of 2014, a 1 percent increase compared with the first quarter of 2013. After adjusting for the impact of foreign currency, total CRM sales increased 3 percent.

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,070.40 +46.34 0.26%
S&P 500 2,114.49 +6.20 0.29%
NASDAQ 5,016.9290 +11.5380 0.23%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs